27932982|t|Impact of CYP2C19 Variants on Clinical Efficacy of Clopidogrel and 1- Year Clinical Outcomes in Coronary Heart Patients Undergoing Percutaneous Coronary Intervention
27932982|a|The impact of pharmacogenetic variants of cytochrome P450 2C19 (CYP2C19) on clopidogrel -mediated effects on platelet inhibition, inflammatory response and endothelial function, as well as risk of major adverse cardiovascular events (MACE), in coronary heart patients undergoing percutaneous coronary intervention (PCI) was investigated. To this end, we assessed the residual platelet aggregation rate (RPA), maximal aggregation rate (MAR) and plasma levels of sCD40L, sP-selectin, MMP-9, sVCAM-1 and sE-selectin after 24 h of PCI in 559 patients treated with clopidogrel and followed up for 1 year for evidence of MACE. CYP2C19(*)2 and (*)3 variants were identified using a clopidogrel -sensitive gene detection kit. Our results showed higher RPA and MAR as well as increased sE-selectin, sCD40L, sP-selectin, MMP-9, and sVCAM-1 levels in CYP2C19 intermediate metabolizer (IM, CYP2C19(*)1 / (*)2, or (*)1 / (*)3), poor metabolizer (PM, CYP2C19(*)2 / (*)2, (*)2 / (*)3, or (*)3 / (*)3) and combined IM+PM groups, relative to those in extensive metabolizers (EM, CYP2C19(*)1 /(*)1). In total, 519 patients completed 1 year of follow-up, among which 69 (13.3%) experienced MACE. The risk of MACE in CYP2C19 IM+PM patients was 2.664 times higher than that in CYP2C19 EM patients (OR = 2.664 (1.397-5.193), P = 0.004). The data suggest that CYP2C19(*)2 and (*)3 variants modulate the drug efficacy of clopidogrel in coronary heart patients undergoing PCI and further enhance the risk of MACE. Accordingly, CYP2C19 pharmacogenetic profiling may be beneficial for coronary heart patients undergoing PCI to predict the efficacy of treatment with clopidogrel. We propose that IM and PM patients should benefit from treatment with higher clopidogrel doses to improve efficacy and reduce the incidence of MACE.
27932982	10	17	CYP2C19	T017	UMLS:C1332828
27932982	18	26	Variants	T017	UMLS:C0678941
27932982	51	62	Clopidogrel	T103	UMLS:C0070166
27932982	131	165	Percutaneous Coronary Intervention	T058	UMLS:C1532338
27932982	180	204	pharmacogenetic variants	T038	UMLS:C4277630
27932982	208	228	cytochrome P450 2C19	T103	UMLS:C0960580
27932982	230	237	CYP2C19	T103	UMLS:C0960580
27932982	242	253	clopidogrel	T103	UMLS:C0070166
27932982	275	294	platelet inhibition	T038	UMLS:C0302106
27932982	296	317	inflammatory response	T038	UMLS:C1155266
27932982	445	479	percutaneous coronary intervention	T058	UMLS:C1532338
27932982	481	484	PCI	T058	UMLS:C1532338
27932982	533	567	residual platelet aggregation rate	T058	UMLS:C0920267
27932982	569	572	RPA	T058	UMLS:C0920267
27932982	610	623	plasma levels	T058	UMLS:C0427425
27932982	627	633	sCD40L	T058	UMLS:C2825885
27932982	635	646	sP-selectin	T058	UMLS:C3890352
27932982	648	653	MMP-9	T103	UMLS:C0165519
27932982	655	662	sVCAM-1	T103	UMLS:C0078056
27932982	667	678	sE-selectin	T058	UMLS:C3890402
27932982	693	696	PCI	T058	UMLS:C1532338
27932982	713	725	treated with	T058	UMLS:C0332293
27932982	726	737	clopidogrel	T103	UMLS:C0070166
27932982	742	753	followed up	T058	UMLS:C1522577
27932982	787	798	CYP2C19(*)2	T017	UMLS:C1707181
27932982	803	807	(*)3	T017	UMLS:C1707182
27932982	808	816	variants	T017	UMLS:C0678941
27932982	841	852	clopidogrel	T103	UMLS:C0070166
27932982	864	882	gene detection kit	T062	UMLS:C1517481
27932982	903	913	higher RPA	T033	UMLS:C0243095
27932982	943	954	sE-selectin	T103	UMLS:C0115305
27932982	956	962	sCD40L	T103	UMLS:C0167627
27932982	964	975	sP-selectin	T103	UMLS:C0134835
27932982	977	982	MMP-9	T103	UMLS:C0165519
27932982	988	995	sVCAM-1	T103	UMLS:C0078056
27932982	1006	1038	CYP2C19 intermediate metabolizer	T033	UMLS:C3203684
27932982	1044	1055	CYP2C19(*)1	T017	UMLS:C1707180
27932982	1058	1062	(*)2	T017	UMLS:C1707181
27932982	1067	1071	(*)1	T017	UMLS:C1707180
27932982	1074	1078	(*)3	T017	UMLS:C1707182
27932982	1103	1114	CYP2C19(*)2	T017	UMLS:C1707181
27932982	1117	1121	(*)2	T017	UMLS:C1707181
27932982	1123	1127	(*)2	T017	UMLS:C1707181
27932982	1130	1134	(*)3	T017	UMLS:C1707182
27932982	1139	1143	(*)3	T017	UMLS:C1707182
27932982	1146	1150	(*)3	T017	UMLS:C1707182
27932982	1165	1177	IM+PM groups	T033	UMLS:C0243095
27932982	1228	1239	CYP2C19(*)1	T017	UMLS:C1707180
27932982	1240	1245	/(*)1	T017	UMLS:C1707180
27932982	1291	1300	follow-up	T058	UMLS:C1522577
27932982	1347	1359	risk of MACE	T033	UMLS:C1273410
27932982	1363	1376	CYP2C19 IM+PM	T033	UMLS:C0243095
27932982	1422	1429	CYP2C19	T017	UMLS:C1332828
27932982	1503	1514	CYP2C19(*)2	T017	UMLS:C1707181
27932982	1519	1523	(*)3	T017	UMLS:C1707182
27932982	1524	1532	variants	T017	UMLS:C0678941
27932982	1563	1574	clopidogrel	T103	UMLS:C0070166
27932982	1613	1616	PCI	T058	UMLS:C1532338
27932982	1641	1653	risk of MACE	T033	UMLS:C1273410
27932982	1668	1675	CYP2C19	T017	UMLS:C1332828
27932982	1676	1701	pharmacogenetic profiling	T038	UMLS:C4277630
27932982	1759	1762	PCI	T058	UMLS:C1532338
27932982	1805	1816	clopidogrel	T103	UMLS:C0070166
27932982	1873	1882	treatment	T058	UMLS:C0087111
27932982	1895	1906	clopidogrel	T103	UMLS:C0070166